Transmedics Group Inc [TMDX] stock is trading at $111.50, up 19.64%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TMDX shares have gain 23.92% over the last week, with a monthly amount glided 47.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
Transmedics Group Inc [TMDX] stock has fluctuated between $55.00 and $177.37 over the past year. Currently, Wall Street analysts expect the stock to reach $105 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $111.50 at the most recent close of the market. An investor can expect a potential drop of -5.83% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 488.23M for the trailing twelve months, which represents a growth of 48.21%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.18 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 106.58 points at the first support level, and at 101.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 118.67, and for the 2nd resistance point, it is at 125.85.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 9.10. As well, the Quick Ratio is 8.32, while the Cash Ratio is 5.62. Considering the valuation of this stock, the price to sales ratio is 7.72, the price to book ratio is 14.16 and price to earnings (TTM) ratio is 85.64.
Transactions by insiders
Recent insider trading involved EDWARD BASILE, Director, that happened on May 09 ’25 when 6000.0 shares were purchased. Chief Commercial Officer, Khayal Tamer I completed a deal on Mar 03 ’25 to sell 2407.0 shares. Meanwhile, Officer Gordon Stephen bought 5942.0 shares on Mar 04 ’25.
